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Abstract
Introduction: The aim of the study was to measure the concentrations of vitamin D in serum of COPD patients with chronic re-
spiratory failure in comparison to healthy control group. The correlation between the levels of vitamin D in serum and the selected 
clinical, spirometric and blood gas parameters was the additional aim of the study.
Material and methods: The study included 61 patients with diagnosed COPD in stadium of chronic respiratory failure (45 men 
and 16 women) and 37 healthy controls (19 men and 18 women). The following procedure were performed in all studied subjects: 
detailed history (especially: daily activity, diet, tobacco and alcohol use), post-bronchodilator spirometry, assessment of 25(OH)D 
in serum and for COPD group only blood gas analysis. Recruitment for the study was conducted from November to April. Statis-
tical analysis was performed using the following statistical methods: t-Student test, Mann-Whitney U test, Spearman correlation 
test and Chi-kwadrat test.
Results: There was no significant differences between COPD and control group for the levels of 25(OH)D in serum. Median and 
lower; upper quartile were respectively following: 24,75 nmol/l (16,9; 36,4) vs. 24,06 nmol/l (16,3; 37,2), p=0,69. Vitamin D 
deficiency was present in 60 COPD patients (98,3% of all patients) and in 36 control group subject (97,3% of all healthy volun-
teers). The difference was not statistically significant. The levels of vitamin D in serum did not significantly correlated with any 
of studied parameters (spirometry, blood gas, age, the level of activity, BMI, tobacco smoke exposure and others). However, the 
level of activity in COPD group correlated positively with spirometry values and negatively with age and number of exacerbations.
Conclusion: The results of the study showed that in autumn-winter time in Poland there are very frequent deficiency of vitamin 
D in serum not only in COPD patients in respiratory failure stage but also in elderly healthy persons. However, in contrary to 
expectations the deficiency of vitamin D in COPD patients with respiratory failure were similar to that seen in healthy persons. 
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Introduction
Chronic obstructive pulmonary disease 
(COPD) of appropriate intensity and duration 
may lead to the development of respiratory 
failure, initially latent, and then at rest together 
with right ventricular failure. The lower refer-
ence limit for partial pressure for oxygen (PaO2) 
of 60 mmHg corresponds to oxygen saturation 
of arterial blood haemoglobin of approximately 
90%. Improving the prognosis for COPD patients 
with chronic respiratory failure is possible thanks 
to long-term oxygen therapy, which reduces 
the involuntary spasm of pulmonary vessels in 
response to hypoxia, decreases pressure in the 
pulmonary circulation and significantly pro-
longs life. Recently, COPD has no longer been 
regarded as a disease limited to the respiratory 
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system only. Extrapulmonary disorders induced 
or exacerbated by COPD include atherosclero-
sis, thrombophilia, cachexia, gastrooesophageal 
reflux, anxiety-depressive disorder, myopathy, 
increased carcinogenesis even after quitting to-
bacco smoking, osteoporosis with pathological 
fractures, diabetes type 2, metabolic syndrome, 
and circulatory insufficiency. Osteoporosis and 
muscle weakness can simultaneously result from 
concomitant vitamin D insufficiency [1]. 
Vitamin D is a hormone synthesised in the 
skin due to solar ultraviolet radiation with a 
wavelength of 290–315 nm (UV-B). The substrate 
is ergosterol or 7-dehydrocholesterol, precursor 
in endogenous synthesis of cholesterol. Longer 
exposure does not lead to overproduction due to 
photolysis. Vitamin D is entirely 25-hydroxylated 
in the liver, thus the serum level of the formed 
25-hydroxyvitamin D (25(OH)D) reflects vitamin 
D concentration in the body reliably. Active 
1,25-dihydroxyvitamin D (1,25(OH)2D) is formed 
in the cells of proximal tubules and hormonally 
acts via the vitamin D receptor present in most 
cells [2, 3]. Synthesis of 1,25(OH)2D is strictly 
regulated, and the catabolism of 25(OH)D and 
1,25(OH)2D is very efficient. The active form of 
vitamin D increases absorption of calcium and 
phosphorus from bowel contents, stimulates 
production of bone matrix proteins, facilitates 
bone mineralisation, acts antiproliferatively on 
parathyroid glands, conditions proper strength 
of muscle contractions, reduces risk of falls, 
affects cellular angiogenesis, division, differenti-
ation and apoptosis as well as functioning of the 
immune system [2, 3]. A correlation of vitamin 
D insufficiency with a number of disorders has 
been found, and lower vitamin D concentration 
is associated prognostically with the increased 
risk of death by 35% [4]. The occurrence and 
exacerbation of disorders depend considerably 
on lifestyle, which also affects vitamin D con-
centration. Limited physical activity decreases 
exposure to UV-B, and in obesity, the excess fatty 
tissue captures vitamin D. Presently, the lower ref-
erence value for 25(OH)D is 30 ng/ml (75 nmol/l). 
The levels of 25(OH)D serum concentration are 
as follows: deficiency < 25 nmol/l; insufficiency 
25–50 nmol/l; suboptimal level 50–75 nmol/l; 
recommended level 75–250 nmol/l, toxicity > 250 
nmol/l [2, 3]. Vitamin D insufficiency is common 
in countries of the temperate zone; in the Polish 
population studies similar results are presented, 
and it is regular vitamin D supplementation that 
significantly affects its reserves. Some researches 
were conducted using proper methodology, but 
in small groups of patients; and the only major 
Polish study is based on populations of big cities, 
without exclusion criteria or information about 
concomitant disorders and supplementation 
[5–8]. Biological relevance of vitamin D is still 
being reassessed: as a result, the minimum rec-
ommended concentration was changed, which 
had previously been 5 ng/ml. 
COPD sufferers are more likely to have vi-
tamin D insufficiency due to limited physical 
activity, frequent indoor stay, premature skin 
ageing, temporary or long-term use of glucocor-
ticoids, unbalanced diet. Glucocorticoid therapy 
exacerbates osteoporosis by acting on calcium 
metabolism, sex hormones and directly affecting 
bone tissue and myopathy [9, 10], starting from 
daily doses of prednisone of 7–7.5 mg. Systemic 
inflammation and sedentary lifestyle exacerbate 
calciuria and osteopenia in mechanisms indepen-
dent of vitamin D [1]. In the COPD Assessment 
Test (CAT) [11], 2 out of 8 items: “I am very limited 
doing activities at home” and “I have no energy 
at all” share the characteristics of a variety of 
other conditions as well vitamin D insufficiency. 
Vitamin D concentrations in COPD sufferers have 
been evaluated more and more often in the world 
literature [12–15], whereas there is a shortage of 
Polish studies of this type. Attempts have been 
made to find a correlation between vitamin D con-
centrations and spirometric parameters in huge 
populations, without specifying the participant’s 
disease. Mean FEV1 (forced expiratory volume in 
one second) and mean FVC (forced vital capacity) 
were lower in the quintile of the lowest vitamin 
D concentration in comparison to the quintile of 
the highest concentration; these differences were 
still valid even after taking into account active 
pastime forms [16]. Another study has revealed 
a significant correlation only in overweight and 
obese men [17]. In the Norwegian population, 
a chance increased 2.4 times for the abnormal 
FEV1/FVC% at the level of 25(OH)D <50 nmol/l, 
but this concerned active smokers only [18]. In 
patients diagnosed with COPD, emphysema or 
chronic bronchitis, a significantly lower 25(OH)
D level was observed [19]. Janssens et al. noticed 
all year long 25(OH)D concentrations lower by 
33% in COPD patients of GOLD stage 4 in com-
parison to controls [14]. In the NHANES study 
3rd Edition, no significant differences were ob-
served of 25(OH)D level in those diagnosed with 
emphysema and chronic bronchitis as compared 
to others, but the correlation of mean FEV1 and 
25(OH)D was stronger than in controls [16]. Low 
vitamin D concentrations in autumn and winter 
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may facilitate the production of inflammatory 
cytokines and more frequent COPD exacerbations. 
The primary objective of the study was to 
compare 25(OH)D levels in COPD patients in re-
spiratory failure stage with the control group 
and to analyse the correlation of 25(OH)D con-
centration with selected clinical, gasometric and 
spirometric parameters.
Materials and methods 
The recruitment of the study group took 
place in the Domiciliary Oxygen Therapy Team 
of the Pulmonary Medicine District Hospital in 
Wodzisław Śląski, Poland, and in the Pulmon-
ology Clinic of the Central Clinical Hospital of 
the Medical University of Silesia (CSK ŚUM) in 
Katowice, Poland. The controls were inhabitants 
of the same area as the patients, of similar age, if 
possible, flatmates (usually the patients’ spouses). 
61 COPD patients and 37 controls were recruited, 
who fulfilled the inclusion and exclusion criteria. 
The study was financed by the Medical University 
of Silesia within the scope of statutory research 
of the Chair and Clinic of Pulmonology. The ap-
proval of the Bioethical Committee of the Medical 
University of Silesia in Katowice was obtained.
Inclusion criteria to the study group were 
the following:
— giving a written informed consent for parti-
cipation,
— diagnosis of COPD, in spirometry persistent 
obstruction in post-bronchodilator spirome-
try (FEV1%VC measured 15 minutes after 
inhaling 400 µg salbutamol < 70%),
— chronic respiratory failure with indications 
for LTOT (at least 3-month history of hypo-
xaemia, not associated with disease exacerba-
tion of PaO2 ≤ 55 mmHg or PaO2 56–60 mm 
Hg together with at least one of the following: 
radiological or ultrasonographic features of 
pulmonary hypertension, polycythemia with 
the peripheral blood haematocrit of ≥ 55%, 
features of right ventricular hypertrophy in 
ECG),
—  above 18 years of age,
— stable disease in the last 4 weeks.
Inclusion criteria to the control group were 
as follows: 
— giving a written informed consent for parti-
cipation,
— lack of respiratory disorders or symptoms,
— normal spirometry values,
—  above 18 years of age
— lack of acute infections in the last 4 weeks.
Exclusion criteria (both groups) included 
the following:
• pregnancy,
• severe renal failure or severe liver impairment, 
or other diseases affecting vitamin D concen-
tration,
• using medicinal preparations and dietary sup-
plements with vitamin D or cod-liver oil within 
the last 3 months,
• contraindications to spirometry (recent oph-
thalmic surgery, coronary or cerebrovascular 
incident within the last month, pneumothorax, 
haemoptysis, aortic aneurysm, severe dyspno-
ea excluding the participant’s cooperation).
In the study group, information was collected 
about COPD exacerbations, diet, stimulants and 
physical activity; post-bronchodilator spirometry 
and gasometry of arterialised blood from the ear-
lobe were performed; venous blood was collected 
to determine 25(OH)D serum level. In the control 
group, information was collected about diet, stim-
ulants and physical activity; post-bronchodilator 
spirometry was performed; venous blood was 
collected to determine 25(OH)D concentration. 
Patients were recruited from November to April 
— to avoid the impact of more intense summer 
sunlight on the measurement results, without re-
peating in summer and early autumn. Spirometry 
with the flow-volume loop was performed with 
Master Screen Pneumo (Carefusion, Yorba Linda, 
USA) (Wodzisław Śląski) and Master Lab (Jaeger® 
Carefusion, Yorba Linda, USA) (Katowice) spi-
rometers. Domiciliary Oxygen Therapy in Poland 
is financed by the Polish National Health Fund 
which requires two spirometry tests during the 
year. As spirometry parameters in COPD without 
exacerbations decrease steadily with age, and 
routine spirometry is not recommended more 
often than every 3 years [11], spirometry done 
within the last 6 months during a recruitment 
visit was accepted in the study group, unless 
exacerbations were noted. Gasometry of arterial 
blood at rest was replaced with less invasive 
earlobe arterialised capillary blood gas analysis 
[20, 21]. Gasometry was performed directly on 
blood collection in the same room using the blood 
gas analysers: AVL Compact (Roche Diagnostic, 
Rotkreuz, Switzerland) (Wodzisław Śląski) and 
Gem® Premier 3000 (Wefren Group IVD, Barce-
lona, Spain) (Katowice). To arterialise the blood, 
Neo-Capsiderm ointment (Herbapol Poznań) was 
used while rubbing the earlobe. Gasometry was 
performed in the sitting position, following an at 
least two-hour break in oxygen supplementation. 
25(OH)D serum concentration was determined in 
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the Function Tests Laboratory of the Pulmonology 
Department of CSK ŚUM in Katowice-Ligota with 
the use of 25OH Vitamin D direct day ELISA kit 
(Immundiagnostic AG, Bernsheim, Germany). 
The blood was centrifuged to obtain the serum, 
and frozen at the temperature of –72 oC, which 
was caused by the necessity of simultaneous 
analysis of 80 specimens. Freezing specimens 
does not affect the measurement results. 
To evaluate physical activity, 5 items in a 
questionnaire were used. Other questionnaire 
points concerned the following: present or past 
tobacco smoking including the number of pack-
years of smoking, severity of coughing up spu-
tum, osteoporosis, pathological fractures. COPD 
patients were also asked about exacerbations 
within the last 3 years requiring treatment in a 
hospital ward, at home, in ICU. Statistical anal-
ysis was done with the Statistica 10 programme 
(Statsoft Polska). For investigating normality of 
distribution, the Shapiro-Wilk test was used. Dif-
ferences between the groups were assessed with 
the t-Student test (normal distribution in both 
groups) or the U-Mann-Whitney test (nonpara-
metric distribution). The analysis of correlation 
was done with Spearman’s rank correlation coef-
ficient, as at least one of the analysed parameters 
always had abnormal distribution. The statistical 
significance level was p < 0.05. A comparison 
of prevalence of vitamin D insufficiency in the 
groups was done with the chi-squared test. The 
results were graphically depicted using box and 
bar charts.
Results
98 individuals were recruited: 61 patients 
aged 54–88 into the study group, and 37 people 
aged 57–93 as controls. The mean age in the study 
group was 71.8 years (± 6.9 years), in the control 
group 69.7 years (± 8.2 years). They did not dif-
fer significantly as for age. The mean number of 
pack-years of smoking in the study group was 47 
(± 20); only 1 control reported smoking tobacco. 
The control group comprised 19 men and 18 
women. A smaller number of controls and gender 
differences were caused by not recruiting some 
of the spouses or flatmates due to: the patient 
living alone, considerable airway obstruction 
in 12 individuals, vitamin D supplementation, 
contraindications to spirometry. The study group 
included 45 men and 16 women. Initially, 85 
COPD patients with chronic respiratory failure 
had given their consent. From these, 24 indi-
viduals were excluded due to: falsely elevated 
FEV1%VC > 70% caused by severe dyspnoea 
and short time of forced expiration, vitamin D 
supplementation, contraindications to spirom-
etry. The demographic data for both groups are 
presented in Table 1.Vitamin D serum concen-
trations did not differ significantly between the 
study and control groups, being respectively 
[median and (lower and upper quartile)]: 24.75 
nmol/l (16.9; 36.4) vs. 24.06 nmol/l (16.3; 37.2), 
p = 0.69. The result is presented in Figure 1. 
Basing on the clinical interpretation of 25(OH)
D concentration, COPD patients were divided 
Table 1. Demographic data for study and control group
Study group Control group
Age (years) 71.8 (± 6.9) 69.7 (± 8.2)
Men/women 45/16 19/18
FEV1 % predicted* 36.9 (27.4; 51.7) 109.0 (95.7; 119.0)
FVC % predicted* 61.0 (52.6; 73.5) 108.6 (93.0; 115.0)
FEV1%FVC* 46.2 (39.2; 58.1) 80.6 (76.7; 83.0)
BMI (kg/m2) 29.7 (25.2; 33.2) 27.5 (25.5; 36.2)
PaO2 (mm Hg) 51.0 (48.0; 54.0) –
PaCO2 (mm Hg) 46.0 (42.0; 50.0) –
Ph 7.42 (7.40; 7.44) –
Pack years of smoking 47 (± 20) –
Serum vitamin D level (nmol/l) 24.75 (16.9; 36.4) 24.06 (16.3; 37.2)
PaCO2 — partial pressure of carbon dioxide in arterial blood, FEV1 — forced expiratory volume in one second; FVC — forced vital capacity; BMI — body mass index
*Data are presented as arithmetic mean and standard deviation for normalized parameter (age); or median and lower/upper quartile for parameters with abnormal 
distribution (other parameters)
Statistical differences between the test and control groups when p < 0.05 were marked 
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Figure 1. Serum 25(OH)D level of severe chronic obstructive pulmo-
nary disease patients with chronic respiratory failure vs control group
Table 2. Clinical interpretation of serum 25(OH)D level for study and control group
Serum 25(OH)D level [nmol/l]
Deficiency 
0–25
Insufficiency 
25–50
Suboptimal 
50–75
Recommended 
75–250
Study group 32 23 5 1
Control group 19 13 3 1
into subgroups of: deficiency, insufficiency, 
suboptimal, and recommended levels of vita-
min D. None of the patients had toxic vitamin 
D concentration. The study and control groups 
did not differ significantly in the subgroups. 
Vitamin D insufficiency below the current norm 
was observed in 60 COPD patients (98.3%) and 
in 36 controls (97.3%) without statistically sig-
nificant difference. The results are presented in 
Table 2 and Figure 2. Vitamin D levels did not 
differ significantly between individual months. 
Type II hypercapnic respiratory failure occurred 
in 39 of 61 patients in the study group.
Only 4 patients in the study group declared 
using oral glucocorticoids; statistical analysis 
could not be performed due to the lower number 
of patients. 37 COPD patients declared applying 
inhaled glucocorticoids. Excluding those using 
oral glucocorticoids, 25(OH)D serum levels did 
not differ significantly between COPD patients 
applying inhaled glucocorticoids and other COPD 
patients, and they respectively were [median and 
(lower and upper quartile)]: 28.2 nmol/l (17.6; 
43.2) vs. 24.5 nmol/l (13.5; 36.4), p = 0.60. The 
result is presented in Figure 3. 
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Figure 2. Clinical interpretation of 25(OH)D concentration into sub-
groups of: deficiency, insufficiency, suboptimal, and recommended 
levels of vitamin D for study and control group
Figure 3. Serum 25(OH)D levels between chronic obstructive pulmonary dis-
ease (COPD patients using inhaled glucocorticoids and other COPD patients
No statistically significant correlation was 
found of vitamin D concentration with the fol-
lowing parameters: clinical (age, BMI, activity 
assessment, nutrition, number of exacerbations, 
severity of coughing up sputum, number pack-
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Figure 4. Correlation for vitamin D concentration with the age, body mass index (BMI), activity assessment, nutrition, number of exacerbations, 
severity of coughing up sputum, number pack-years of smoking
Serum 25(OH)D [nmol/l]
COPD group
Serum 25(OH)D [nmol/l]
Control group
Age 
BMI 
Activity assessment 
Nutrition 
Severity of coughing up sputum 
Number of exacerbations 
Number pack-years of smoking 
years of smoking), spirometric (FEV1%, FVC%, 
FEV1%VC), gasometric (pO2, pCO2, pH). As for 
other parameters, the following statistically sig-
nificant correlation coefficients were obtained: 
positive between FEV1%, FVC%, FEV1%VC and 
activity, negative between pCO2 and FEV1%, 
FVC% and pH, pCO2 and pO2, negative between 
the number of exacerbations and activity and 
between activity and age (Fig. 4).
Discussion
Despite strong presumptions, no statistically 
significant difference was observed comparing 
vitamin D serum concentration in COPD patients 
with chronic respiratory failure and controls. 
Vitamin D insufficiency occurs commonly in 
countries with moderate latitude, especially in 
seasons with less sunlight. Less physical activity 
in the study group did not affect the median of 
vitamin D concentration, showing no statistically 
significant correlation of 25(OH)D concentration 
with activity. Paradoxically, this might be caused 
by the recruitment from late autumn to early 
spring in order to avoid the impact of sunlight 
on the results. The choice of the seasons might 
have smooth and blur possible differences below 
the statistical significance due to lack of vitamin 
D synthesis in the skin. Among hypotheses, two 
presumptions are dependent on sun exposure: less 
physical activity and premature skin ageing. This 
poses a question: Would a statistically significant 
difference be recognised while determining vita-
min D concentration at the end of summer? Due 
to the fact that 25(OH)D concentrations will differ 
after several cloudy or rainy days or following 
intense summer sunlight exposure, collecting ma-
terial to determine 25(OH)D concentration should 
take place within a few days. Less physical activity 
does not have to equal less exposure of the skin to 
the sun: a patient sitting during many hours in the 
garden may have a higher 25(OH)D serum concen-
tration than a patient of the same degree of fitness, 
living in the northern side of a building without a 
lift. The opposite situation may be observed in a 
healthy individual who leads an indoor sedentary 
lifestyle and rarely goes for a walk. 
The more severe COPD stage and more fre-
quent exacerbations, the greater the frequency 
of using systemic glucocorticoids- hence their 
catabolic influence on vitamin D might have led 
to false positive results. Low socioeconomic sta-
tus associated with COPD sufferers, and thus a 
possibly monotonous, unhealthy diet might not 
have been valid for the studied population of 
Upper Silesia, where the majority were former 
employees of a coal mine, with pension 2-3 times 
higher than the average one in Poland.
A comparison of obtained results with those 
by other researchers has revealed both the com-
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patible and divergent results. Jackson et al. have 
presented significantly lower concentration of 
25(OH)D = 41.5 nmol/l in the COPD subgroup vs 
controls 54.8 nmol/l, (p = 0.03); however, their 
COPD patients did not have respiratory failure 
and relatively high 25(OH)D concentrations have 
resulted from participants recruited both in sum-
mer and winter [19]. The authors have also pre-
sented a graph of the group of COPD patients with 
25(OH)D concentration statistically significantly 
lower by 14.6 nmol/l in winter in comparison 
to summer, but without differentiating between 
subjects who take supplements and those who 
do not. Janssens et al. [14] have described mean 
25(OH)D concentration of 40 nmol/l in 30 COPD 
patients of GOLD Stage 4 in comparison to 61.5 
nmol/l in the control group [14], but they have 
not presented differences in the COPD group vs 
controls in individual seasons, which could make 
it possible to compare with own results [14]. 
 No correlation was found of ventilatory 
parameters with 25(OH)D concentration in the 
study and control groups. Some researchers have 
reported statistically significant correlation in 
various subgroups of both controls and COPD 
patients [16–18]. The publications have lacked 
critical cause-and-effect analysis: decreased 
spirometric parameters have meant decreased 
physical fitness, less exposure to UV-B, and thus 
lower 25(OH)D concentrations. The reason for 
not finding a correlation of ventilatory parameters 
with 25(OH)D concentration may be a relatively 
small number of participants in the study group 
in comparison to the quoted articles (NHANES: 
more than 10,000 participants). An alternative 
reason for lack of correlation between activity 
parameters and 25(OH)D concentrations might 
be accurate characteristics, homogenousness and 
narrowing of the study group (patients with very 
severe COPD in the stage of respiratory failure), 
while in other studies [16–18], the population was 
not limited to COPD and patients were in various 
stages of disease, which might have facilitated the 
observation of a connection.
Statistically significant positive correlation 
coefficients of activity with ventilatory param-
eters and the negative correlation coefficient 
with age prove the relevance and simplicity of 
questionnaire items and genuineness of the re-
sponses given. The correlations found between 
spirometric and gasometric parameters result 
from COPD pathophysiology. An interesting issue 
discussed in the literature is the attempt to assess 
the correlation between 25(OH)D concentration 
and risk of COPD exacerbations. However, such 
data were not to be collected owing to the short 
observation time.
Study limitation
The authors constantly use gasometry with 
arterialised blood of the earlobe due to less inva-
siveness compared to arterial blood. The aware-
ness of the possibility of a slight understatement 
of the pO2 value using this method, which was 
discussed by some authors, did not influence the 
obtained results [22]. GOLD classification is not 
useful in grading treatment and therapeutic in-
terventions in patients in terminal stage of COPD. 
Therefore, the division of patients into GOLD 
in COPD with respiratory failure in our publi-
cation is pointless, with predictable dominance 
of patients in stages III and IV and in groups C 
and D. A large part of the study group, as many 
as 16 people from 61 presented pCO2 values in 
the range of 44–46 mmHg. With the mandatory 
upper limit of pCO2 = 45 mm Hg, repeating daily 
or hourly gas measurements in this group may re-
sult in completely different rates of patients with 
type I and II respiratory failure due to tolerable 
pCO2 measurement bias and circadian fluctua-
tions. Therefore, in the article, the percentage 
of patients with type I and II respiratory failure 
should only be considered as approximate in 
such a group. Accordingly, further analyses of 
possible association of vitamin D levels with 
type of respiratory failure in our opinion have 
no scientific basis.
Conclusion
Vitamin D insufficiency is very common in 
autumn and winter in Poland in elderly COPD 
sufferers and healthy individuals. 25(OH)D serum 
concentration in patients with severe COPD and 
chronic respiratory failure is not significantly 
lower as compared to the control group.
No correlation was observed of ventilatory, 
gasometric, or activity parameters with 25(OH)D 
concentration in COPD patients.
The questionnaire responses revealed that 
the activity of patients with advanced COPD and 
respiratory failure decreased.
Statistically significant positive correlation 
coefficients were found between patients’ activity 
and FEV1%, FVC%, FEV1%FVC and pO2 , and a 
negative correlation coefficient between activity 
and age. 
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